Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inject Rebif New Formulation (RNF) In a multi-dose cartriDGE (BRIDGE)

Registry ID

EUCTR2009-013333-24

Source registry

EUCTR

Status

Completed

Phase

PHASE4

Sponsor

MERCK SERONO SPA

Start date

2009-08-03

Last update

2026-08-16

Conditions

• RELAPSING MULTIPLE SCLEROSIS

Summary

To assess adherence to treatment in subjects with relapsing multiple sclerosis (RMS) switching from other injectables DMDs using ReBiSmart to self-inject Rebif New Formulation (RNF) in a multi-dose cartridge

Locations

• , , Italy

Related clinical trials

• A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with Relapsing Multiple Sclerosis

View on source registry